The global mRNA therapeutics market size is expected to reach USD 37.76 billion by 2030. It is expected to expand at a CAGR of 1.7% from 2022 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs.
The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.
mRNA therapeutics Market Size & Market Analysis
Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favourable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.
For instance, in March 2022, The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.
As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.
mRNA therapeutics Market Size & Market Analysis
The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer or metastasis cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.
Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.
List of main Players in the mRNA Therapeutics Market Size & Market Analysis :
Moderna, Inc.
BioNTech SE
CureVac N.V.
Arcturus Therapeutics
Translate Bio, Inc.
GSK plc.
Argos Therapeutics Inc.
Sangamo Therapeutics, Inc.
Pfizer Inc.
AstraZeneca plc.
CRISPR Therapeutics AG
Source : https://www.researchandmarkets.com/reports/5644939/global-mrna-therapeutics-market-size-share-and#:~:text=The%20global%20mRNA%20therapeutics%20market%20size%20is%20expected,infectious%20diseases%20like%20diabetes%2C%20HIV%2C%20cancer%2C%20and%20CVDs.